EP1865980A4 - ABUSEFUL AMPHETAMINE PRODRUGS - Google Patents

ABUSEFUL AMPHETAMINE PRODRUGS

Info

Publication number
EP1865980A4
EP1865980A4 EP06769808A EP06769808A EP1865980A4 EP 1865980 A4 EP1865980 A4 EP 1865980A4 EP 06769808 A EP06769808 A EP 06769808A EP 06769808 A EP06769808 A EP 06769808A EP 1865980 A4 EP1865980 A4 EP 1865980A4
Authority
EP
European Patent Office
Prior art keywords
abuse
resistant amphetamine
amphetamine prodrugs
prodrugs
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06769808A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1865980A2 (en
Inventor
Barney Bishop
Suma Krishnan
Travis Mickle
Rob Oberlender
Christopher Lauderback
James Scott Moncrief
Thomas Piccariello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire LLC
Original Assignee
Shire LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire LLC filed Critical Shire LLC
Publication of EP1865980A2 publication Critical patent/EP1865980A2/en
Publication of EP1865980A4 publication Critical patent/EP1865980A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP06769808A 2005-04-08 2006-04-10 ABUSEFUL AMPHETAMINE PRODRUGS Withdrawn EP1865980A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US66938505P 2005-04-08 2005-04-08
US66938605P 2005-04-08 2005-04-08
US68117005P 2005-05-16 2005-05-16
US75654806P 2006-01-06 2006-01-06
US75995806P 2006-01-19 2006-01-19
PCT/US2006/013221 WO2006121552A2 (en) 2005-04-08 2006-04-10 Abuse-resistant amphetamine prodrugs

Publications (2)

Publication Number Publication Date
EP1865980A2 EP1865980A2 (en) 2007-12-19
EP1865980A4 true EP1865980A4 (en) 2009-11-11

Family

ID=37397039

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06769808A Withdrawn EP1865980A4 (en) 2005-04-08 2006-04-10 ABUSEFUL AMPHETAMINE PRODRUGS

Country Status (6)

Country Link
EP (1) EP1865980A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008535860A (cg-RX-API-DMAC7.html)
BR (1) BRPI0612440A2 (cg-RX-API-DMAC7.html)
CA (1) CA2603873A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007012507A (cg-RX-API-DMAC7.html)
WO (1) WO2006121552A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US8487134B2 (en) 2008-10-09 2013-07-16 Archimica, Inc. Process for the synthesis of amphetamine derivatives
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
US20140073589A1 (en) * 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
WO2018118903A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Noncrushable pill formulatiions
WO2018118902A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Dual-enzyme responsive peptides
DK3459538T3 (da) 2017-09-20 2020-08-03 Sandoz Ag Krystallinske salte af et dextroamfetamin-prodrug
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
EP4098248A1 (en) * 2019-12-30 2022-12-07 Labomed Pharmaceutical Company S.A. Oral solutions comprising lisdexamfetamine salts
JP2023549405A (ja) 2020-11-18 2023-11-24 マインド メディシン， インコーポレイテッド 心理療法を補助するためのｍｄｍａプロドラッグ
EP4447891B1 (en) 2021-12-16 2025-10-01 Labomed Pharmaceutical Company S.A. Container comprising a lisdexamfetamine containing oral solution
EP4561528A1 (en) 2022-07-29 2025-06-04 Labomed Pharmaceutical Company S.A. Lisdexamfetamine containing oral solution

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005407A1 (en) * 1999-07-14 2001-01-25 Shire Laboratories, Inc. Rapid immediate release oral dosage form
WO2005032474A2 (en) * 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3878187A (en) * 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
IL158959A (en) * 2001-05-25 2010-06-30 Cephalon Inc Solid pharmaceutical formulations comprising modafinil
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005407A1 (en) * 1999-07-14 2001-01-25 Shire Laboratories, Inc. Rapid immediate release oral dosage form
WO2005032474A2 (en) * 2003-09-30 2005-04-14 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse

Also Published As

Publication number Publication date
JP2008535860A (ja) 2008-09-04
CA2603873A1 (en) 2006-11-16
BRPI0612440A2 (pt) 2010-11-23
MX2007012507A (es) 2008-03-11
WO2006121552A2 (en) 2006-11-16
WO2006121552A3 (en) 2007-07-05
EP1865980A2 (en) 2007-12-19
WO2006121552A9 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
PL1968612T3 (pl) Proleki dinukleotydowe
GB2424581B (en) Formulations
TWI339780B (en) Stripper
IL187919A0 (en) 4c
IL185773A0 (en) Formulations
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
EP1865980A4 (en) ABUSEFUL AMPHETAMINE PRODRUGS
ZA200800365B (en) Substituted tetrahydroqulnolines
AP2008004705A0 (en) Pnem prodrugs
EP1907710A4 (en) MEANS OF CONSTRUCTION
GB0421294D0 (en) Bioreductively-activated prodrugs
GB0421296D0 (en) Bioreductively-activated prodrugs
GB0515699D0 (en) Prodrugs
HK1117036A (en) Abuse-resistant amphetamine prodrugs
GB2433078B (en) Structural member
GB0513231D0 (en) Clear view
TWM298926U (en) Assembled paintbrush structure
GB0414567D0 (en) Prodrugs
GB0421295D0 (en) Bioreductively-activated prodrugs
AU3292P (en) DP303 Dianella prunina
AU3393P (en) Breakwell xTriticosecale
AU3401P (en) Archise Arctotis fastuosa
PL372159A1 (pl) Dopuszczalny-skrajny gabaryt
GR1007111B (en) Assembled ballot-box
GB0506838D0 (en) Concept seven

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070921

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SHIRE LLC

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PICCARIELLO, THOMAS

Inventor name: MONCRIEF, JAMES SCOTT

Inventor name: LAUDERBACK, CHRISTOPHER

Inventor name: OBERLENDER, ROB

Inventor name: MICKLE, TRAVIS

Inventor name: KRISHNAN, SUMA

Inventor name: BISHOP, BARNEY

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PICCARIELLO, THOMAS

Inventor name: MONCRIEF, JAMES SCOTT

Inventor name: OBERLENDER, ROB

Inventor name: MICKLE, TRAVIS

Inventor name: KRISHNAN, SUMA

Inventor name: BISHOP, BARNEY

Inventor name: LAUDERBACK, CHRISTOPHER

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1117036

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20090915

17Q First examination report despatched

Effective date: 20091229

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PAUL, BERNHARD J

Inventor name: VERBICKY, CHRISTOPHER A

Inventor name: PICCARIELLO, THOMAS

Inventor name: MONCRIEF, JAMES SCOTT

Inventor name: LAUDERBACK, CHRISTOPHER

Inventor name: OBERLENDER, ROB

Inventor name: MICKLE, TRAVIS

Inventor name: KRISHNAN, SUMA

Inventor name: BISHOP, BARNEY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120207

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1117036

Country of ref document: HK